By Colin Kellaher
Life-sciences giant Danaher has agreed to buy Abcam, a supplier of protein consumables, in a deal carrying a total enterprise value of about $5.7 billion, including assumed debt.
Danaher on Monday said it would pay $24 a share in cash for Abcam, a scant 2.7% premium to Friday's closing price of $23.36 for the U.K.-based company.
Danaher said Abcam will operate as a standalone company and brand within its life-sciences segment, furthering its strategy to help map complex diseases and accelerate the drug-discovery process.
Washington-based Danaher said it plans to fund the deal, slated to close in mid-2024, with cash on hand and proceeds from the issuance of commercial paper.
Trading in shares of Abcam was halted premarket on Monday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
08-28-23 0758ET